Literature DB >> 10906156

Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis.

Jan Aten1, Anja Roos1, Nike Claessen1, Esther J M Schilder-Tol1, Ineke J M Ten Berge2, Jan J Weening1.   

Abstract

CD134 (OX40) is a member of the tumor necrosis factor (TNF) receptor (TNFR) family that can be expressed on activated T lymphocytes. Interaction between CD134 and its ligand (CD134L) is involved in costimulation of T and B lymphocyte activation, and in T cell adhesion to endothelium. To examine the possible role of this interaction in the pathogenesis of systemic lupus erythematosus (SLE), expression of CD134 and CD134L on peripheral blood leukocytes was studied, and no significant differences between SLE patients and control individuals were found. Immunohistology on renal biopsies from patients with lupus nephritis or other renal disorders, using a recombinant human CD134-containing chimeric molecule to detect CD134L, demonstrated the abundant presence of CD134L in all cases of proliferative lupus nephritis in a granular distribution predominantly along the epithelial side of the glomerular capillary wall. Confocal laser scanning microscopy indicated colocalization with subepithelial immune deposits. In none of the other renal disorders examined, including nonproliferative forms of lupus nephritis, was glomerular staining for CD134L detected in a similar pattern. Endothelial CD134L expression was frequently observed in different types of vasculitis. CD134 was detected on perivascular infiltrating leukocytes and on part of the tubular epithelium, but not on glomerular resident cells. Immunohistology for several other TNF(R) family members revealed in proliferative lupus nephritis a similar distribution for TNFR1 as was observed for CD134L. In contrast, glomerular expression of TNFR2 was similar in all cases examined. The glomerular presence of CD134L and TNFR1 in proliferative lupus nephritis in association with subepithelial immune deposits may be of pathogenetic significance and have diagnostic value.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906156     DOI: 10.1681/ASN.V1181426

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  32 in total

1.  Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis.

Authors:  Zhao Xiaoyan; R Pirskanen; V Malmstrom; A K Lefvert
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

2.  CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus.

Authors:  S Patschan; S Dolff; A Kribben; J Dürig; D Patschan; B Wilde; C Specker; T Philipp; O Witzke
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

3.  Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis.

Authors:  Yan-bin Zhou; Ren-gao Ye; You-ji Li; Can-mao Xie
Journal:  Rheumatol Int       Date:  2008-09-20       Impact factor: 2.631

4.  Renal atrophy after ischemia-reperfusion injury depends on massive tubular apoptosis induced by TNFα in the later phase.

Authors:  Takaomi Adachi; Noriyuki Sugiyama; Hideo Yagita; Takahiko Yokoyama
Journal:  Med Mol Morphol       Date:  2014-01-10       Impact factor: 2.309

5.  Increased circulating cytokine levels in African American women with obesity and elevated HbA1c.

Authors:  Ariel Williams; Natasha Greene; K Kimbro
Journal:  Cytokine       Date:  2020-01-28       Impact factor: 3.861

Review 6.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

7.  Altered expression of TNFSF4 and TRAF2 mRNAs in peripheral blood mononuclear cells in patients with systemic lupus erythematosus: association with atherosclerotic symptoms and lupus nephritis.

Authors:  Peyman Rajabi; Mahsa Alaee; Kazem Mousavizadeh; Ali Samadikuchaksaraei
Journal:  Inflamm Res       Date:  2012-07-31       Impact factor: 4.575

Review 8.  Genetics of Lupus Nephritis: Clinical Implications.

Authors:  Melissa E Munroe; Judith A James
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

9.  Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus.

Authors:  Sebastian Dolff; Daniel Quandt; Benjamin Wilde; Thorsten Feldkamp; Fan Hua; Xin Cai; Christof Specker; Andreas Kribben; Cees G M Kallenberg; Oliver Witzke
Journal:  Arthritis Res Ther       Date:  2010-07-23       Impact factor: 5.156

Review 10.  Association of the co-stimulator OX40L with systemic lupus erythematosus.

Authors:  Harinder Manku; Deborah S Cunninghame Graham; Timothy J Vyse
Journal:  J Mol Med (Berl)       Date:  2008-12-16       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.